Caffeic acid phenethyl ester : an effective antiviral agent against porcine reproductive and Respiratory Syndrome Virus
Copyright © 2024 Elsevier B.V. All rights reserved..
Porcine Reproductive and Respiratory Syndrome (PRRS) presents a formidable viral challenge in swine husbandry. Confronting the constraints of existing veterinary pharmaceuticals and vaccines, this investigation centers on Caffeic Acid Phenethyl Ester (CAPE) as a prospective clinical suppressant for the Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The study adopts an integrated methodology to evaluate CAPE's antiviral attributes. This encompasses a dual-phase analysis of CAPE's interaction with PRRSV, both in vitro and in vivo, and an examination of its influence on viral replication. Varied dosages of CAPE were subjected to empirical testing in animal models to quantify its efficacy in combating PRRSV infections. The findings reveal a pronounced antiviral potency, notably in prophylactic scenarios. As a predominant component of propolis, CAPE stands out as a promising candidate for clinical suppression, showing exceptional effectiveness in pre-exposure prophylaxis regimes. This highlights the potential of CAPE in spearheading cutting-edge strategies for the management of future PRRSV outbreaks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:225 |
|---|---|
| Enthalten in: |
Antiviral research - 225(2024) vom: 13. Apr., Seite 105868 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cui, Zhanding [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.04.2024 Date Revised 19.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.antiviral.2024.105868 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369800214 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369800214 | ||
| 003 | DE-627 | ||
| 005 | 20240419232444.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240316s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.antiviral.2024.105868 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM369800214 | ||
| 035 | |a (NLM)38490343 | ||
| 035 | |a (PII)S0166-3542(24)00077-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cui, Zhanding |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Caffeic acid phenethyl ester |b an effective antiviral agent against porcine reproductive and Respiratory Syndrome Virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2024 | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Porcine Reproductive and Respiratory Syndrome (PRRS) presents a formidable viral challenge in swine husbandry. Confronting the constraints of existing veterinary pharmaceuticals and vaccines, this investigation centers on Caffeic Acid Phenethyl Ester (CAPE) as a prospective clinical suppressant for the Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The study adopts an integrated methodology to evaluate CAPE's antiviral attributes. This encompasses a dual-phase analysis of CAPE's interaction with PRRSV, both in vitro and in vivo, and an examination of its influence on viral replication. Varied dosages of CAPE were subjected to empirical testing in animal models to quantify its efficacy in combating PRRSV infections. The findings reveal a pronounced antiviral potency, notably in prophylactic scenarios. As a predominant component of propolis, CAPE stands out as a promising candidate for clinical suppression, showing exceptional effectiveness in pre-exposure prophylaxis regimes. This highlights the potential of CAPE in spearheading cutting-edge strategies for the management of future PRRSV outbreaks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiviral agent | |
| 650 | 4 | |a Caffeic acid phenethyl ester | |
| 650 | 4 | |a In vivo | |
| 650 | 4 | |a Porcine reproductive and respiratory syndrome | |
| 650 | 4 | |a Swine viral infections | |
| 650 | 7 | |a caffeic acid phenethyl ester |2 NLM | |
| 650 | 7 | |a G960R9S5SK |2 NLM | |
| 650 | 7 | |a Veterinary Drugs |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Caffeic Acids |2 NLM | |
| 650 | 7 | |a Phenylethyl Alcohol |2 NLM | |
| 650 | 7 | |a ML9LGA7468 |2 NLM | |
| 700 | 1 | |a Zhang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jinlong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jinlong |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Pu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guoxiu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Juanbin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Zhixun |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Xingwen |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xueqing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Pinghua |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yuanfang |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Huifang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zaixin |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Yimei |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Zengjun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antiviral research |d 1983 |g 225(2024) vom: 13. Apr., Seite 105868 |w (DE-627)NLM012601756 |x 1872-9096 |7 nnns |
| 773 | 1 | 8 | |g volume:225 |g year:2024 |g day:13 |g month:04 |g pages:105868 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.antiviral.2024.105868 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 225 |j 2024 |b 13 |c 04 |h 105868 | ||